Drug Discovery and Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Women in Pharma
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • R&D 100 Awards
  • Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50

NIH says still no drug proven safe, effective for treating COVID-19

By Chris Newmarker | April 21, 2020

Coronavirus-COVID-19-CDCThe National Institutes of Health today announced the publishing of new COVID-19 treatment guidelines, and the expert panel producing the guidelines says no drug has yet been proven safe and effective against the virus.

NIH has the new guidelines posted online at covid19treatmentguidelines.nih.gov — and says it will update the guidelines often as new peer-reviewed scientific literature and other authoritative information emerges.

Clinical trials are ramping up for a host of potential coronavirus-fighting drugs.

Drug candidates against COVID-19 include antivirals such as chloroquine or hydroxychloroquine — or the investigational antiviral drug remdesivir. Other possibilities involve host modifiers/immune-based therapy such as convalescent plasma or hyperimmune immunoglobulin, as well as interleukin-6 inhibitors (e.g., sarilumab, siltuximab, tocilizumab) and interleukin-1 inhibitors (e.g., anakinra). For now, NIH is saying that at least for now, there is insufficient clinical data to recommend either for or against the therapies.

NIH is recommending against a number of other options:

  • The combination of hydroxychloroquine plus azithromycin (AIII) because of the potential for toxicities.
  • Lopinavir/ritonavir (AI) or other HIV protease inhibitors (AIII) because of unfavorable pharmacodynamics and negative clinical trial data.
  • Interferons (AIII), because of lack of efficacy in treatment of severe acute respiratory syndrome (SARS) and Middle East respiratory syndrome (MERS) and toxicity.
  • Janus kinase inhibitors (e.g., baricitinib) (AIII), because of their broad immunosuppressive effect.

 


Filed Under: clinical trials, Drug Discovery, Drug Discovery and Development, Genomics/Proteomics, Infectious Disease
Tagged With: coronavirus, National Institutes of Health
 

Tell Us What You Think! Cancel reply

You must be logged in to post a comment.

Related Articles Read More >

Portrait photo of Cardinal Health CFO and soon-to-be CEO Jason Hollar
Cardinal Health’s CFO to move up to corner office
CNS
The CNS drug development drum beat is getting louder
DeepMind
7 ways DeepMind’s AlphaFold is being used in life sciences
Biomarker
Bioanalytical method development and validation using Quanterix’s Simoa platform 

Need Drug Discovery news in a minute?

We Deliver!
Drug Discovery & Development Enewsletters get you caught up on all the mission critical news you need. Sign up today.
Enews Signup
Drug Discovery and Development
  • MassDevice
  • DeviceTalks
  • Medical Design & Outsourcing
  • Medical Tubing + Extrusion
  • Medtech100 Index
  • Medical Design Sourcing
  • Subscribe to our Free E-Newsletter
  • Contact Us
  • About Us
  • Advertise With Us
  • R&D World
  • Drug Delivery Business News
  • Pharmaceutical Processing World

Copyright © 2022 WTWH Media LLC. All Rights Reserved. The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media
Privacy Policy | Advertising | About Us

Search Drug Discovery & Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Women in Pharma
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • R&D 100 Awards
  • Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50